3 of 6
BACK NEXT
Abbott Laboratories
Abbott Laboratories

The drug and medical device maker recently received FDA approval for cholesterol drug Simcor, which could be a worthy contender for Vytorin, a drug created by rivals Merck and Schering-Plough.

And sales of Abbott's important Humira arthritis drug grew 42% over the fourth quarter, a good sign for the company. JPMorgan analyst Michael Weinstein thinks Abbott is worth buying. He expects earnings to grow 14% in 2008.

Abbott currently trades at about 17 times 2008 estimates and offers a dividend yield of 2.6%. And Abbott's dividend has increased 7% annually, on average, over the past five years. To put that in perspective, rivals such as Merck, Wyeth have boosted their payouts to investors by just 1% and 4% on average over the past few years.



NEXT: Federated Investors
Last updated June 20 2008: 1:23 PM ET
More Galleries
Getty family known for its wealth and misfortunes The Getty family may be as famous for its fortune as the misfortune that has dogged its name for years. Here is a brief history of the players in the tumultuous Getty saga. More
The 32 best April Fools' Day gags of 2015 April Fools' Day is here, which means that businesses around the world are letting their guard down. More
World's worst cities for rush hour traffic So you thought your city had the worst rush hour traffic in the world? More

Special Offer